Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Products under Development by Stage of Development | 7 | 1 |
| Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Products under Development by Therapy Area | 8 | 1 |
| Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Products under Development by Indication | 9 | 1 |
| Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Products under Development by Companies | 12 | 2 |
| Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Therapeutics Assessment | 14 | 4 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 1 |
| Assessment by Molecule Type | 17 | 1 |
| Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Companies Involved in Therapeutics Development | 18 | 5 |
| Amura Holdings Limited | 18 | 1 |
| Medivir AB | 19 | 1 |
| Merck &Co., Inc. | 20 | 1 |
| Virobay Inc. | 21 | 1 |
| Wroclawskie Centrum Badan EIT+ Sp. z o.o. | 22 | 1 |
| Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Drug Profiles | 23 | 10 |
| AM-3701 Drug Profile | 23 | 1 |
| AM-3876 Drug Profile | 24 | 1 |
| MIV-711 Drug Profile | 25 | 2 |
| odanacatib Drug Profile | 27 | 3 |
| Small Molecules to Inhibit CTSK for Oncology Drug Profile | 30 | 1 |
| VBY-129 Drug Profile | 31 | 1 |
| VBY-285 Drug Profile | 32 | 1 |
| Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Dormant Projects | 33 | 1 |
| Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Discontinued Products | 34 | 1 |
| Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Featured News &Press Releases | 35 | 13 |
| Jan 28, 2016: Medivir initiates phase IIa study of MIV-711 in knee osteoarthritis | 35 | 1 |
| Sep 15, 2014: Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis | 35 | 2 |
| Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders | 37 | 1 |
| May 21, 2013: Medivir Presents Positive Results From Phase Ia Study With MIV-711 For Treatment Of Skeletal Disorders At 2013 ECTS Annual Meeting | 38 | 1 |
| Oct 13, 2012: Merck Announces Results From Phase II Clinical Trial Of Odanacatib In Post-Menopausal Osteoporosis | 39 | 1 |
| Aug 21, 2012: Medivir Commences Phase Ib Trial Of MIV-711 For Treatment Of Skeletal Disorders | 40 | 1 |
| Jul 11, 2012: Merck Provides Update On Phase III Trial Of Odanacatib For Treatment Of Osteoporosis | 40 | 1 |
| May 28, 2012: Medivir Initiates Phase I Clinical Trial Of MIV-711 For Treatment Of Bone Disorders | 41 | 1 |
| Mar 19, 2012: Medivir To File Application For Initiation Of Phase I Trials Of MIV-711 | 42 | 1 |
| Sep 19, 2011: Merck Announces Presentation Of New Data On Odanacatib Phase III Investigational Cat-K Inhibitor For Osteoporosis At Annual Meeting Of American Society For Bone And Mineral Research | 42 | 2 |
| Oct 18, 2010: Merck Presents New Data On Odanacatib For Treatment of Osteoporosis In Postmenopausal Women at ASBMR Annual Meeting | 44 | 1 |
| Sep 16, 2009: Medivir Presented Its Cathepsin K Program at the Ongoing 31st Asbmr Meeting in Denver, USA | 45 | 1 |
| Sep 14, 2009: New, Long-Term Data For Odanacatib, Merck's Investigational Cat K Inhibitor, Showed Positive Results In Treating Osteoporosis | 46 | 1 |
| Sep 01, 2009: Medivir Broadens Its Bone Disease Portfolio By Designating One Further Candidate Drug (CD), MIV-711 | 46 | 1 |
| Sep 16, 2008: Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Increased Bone Mineral Density (BMD) Over Two Years At Key Fracture Sites In Phase IIB Study | 46 | 2 |
| Appendix | 48 | 2 |
| Methodology | 48 | 1 |
| Coverage | 48 | 1 |
| Secondary Research | 48 | 1 |
| Primary Research | 48 | 1 |
| Expert Panel Validation | 48 | 1 |
| Contact Us | 48 | 1 |
| Disclaimer | 49 | 1 |